capmatinib   

GtoPdb Ligand ID: 7904

Synonyms: INC280 | INCB28060 | Tabrecta®
capmatinib is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Capmatinib (NCB28060) is a novel, oral, ATP-competitive inhibitor of c-MET that was developed by Novartis [2].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 85.07
Molecular weight 412.14
XLogP 3.28
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES CNC(=O)c1ccc(cc1F)c1cnc2n(n1)c(cn2)Cc1ccc2c(c1)cccn2
Isomeric SMILES CNC(=O)c1ccc(cc1F)c1cnc2n(n1)c(cn2)Cc1ccc2c(c1)cccn2
InChI InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
InChI Key LIOLIMKSCNQPLV-UHFFFAOYSA-N
Classification
Compound class Synthetic organic
Approved drug? Yes (FDA (2020))
IUPAC Name
2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
International Nonproprietary Names
INN number INN
9948 capmatinib
Synonyms
INC280 | INCB28060 | Tabrecta®
Comments
Capmatinib (NCB28060) is a novel, oral, ATP-competitive inhibitor of c-MET that was developed by Novartis [2].
Database Links
CAS Registry No. 1029712-80-8
ChEMBL Ligand CHEMBL3188267
GtoPdb PubChem SID 249565587
PubChem CID 25145656
Search Google for chemical match using the InChIKey LIOLIMKSCNQPLV-UHFFFAOYSA-N
Search Google for chemicals with the same backbone LIOLIMKSCNQPLV
Search PubMed clinical trials capmatinib
Search PubMed titles capmatinib
Search PubMed titles/abstracts capmatinib
Search UniChem for chemical match using the InChIKey LIOLIMKSCNQPLV-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone LIOLIMKSCNQPLV